Clinical trial NIVEAU - DSHNHL 2015-01
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma
Cancers | |
---|---|
Organ | Non-Hodgkin lymphoma |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2/3 |
Academic trial | Non |
Sponsor | LYSA LYmphoma |
EudraCT Identifier | 2016-002272-27 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03366272 |
Inclusion criteria | First relapse or progressionAgressive NHLAge > 65 YO or >18 yo and HCT-CI score > 2 or prior ASCT and not eligible for allogeneic transplantation |
Last update |